Nuvation Bio Q2 Earnings Call Highlights

1 hour ago 3

MarketBeat

Sat, August 8, 2026 astatine 4:03 PM CDT 7 min read

Key Points

Interested successful Nuvation Bio Inc.? Here are 5 stocks we similar better.
IBTROZI momentum strengthened: Second-quarter gross reached $31.7 million, including $23.2 cardinal successful U.S. merchandise revenue, up 25% sequentially. About 85% of caller diligent starts were first-line, supporting longer attraction durations and imaginable aboriginal growth.
Safusidenib improvement is expanding: Updated Phase II information successful IDH1-mutant glioma showed a 52% nonsubjective effect complaint and a 79% three-year progression-free endurance rate. Nuvation is adding Phase III and Phase II studies targeting earlier-stage illness and patients who advancement aft vorasidenib.
Balance expanse strengthened: Nuvation held $661 cardinal successful currency and marketable securities astatine June 30 and raised astir $279.1 cardinal successful nett proceeds done convertible notes. Management said its superior should enactment operations done profitability and the anticipated safusidenib launch.

Nuvation Bio (NYSE:NUVB) reported second-quarter full gross of $31.7 million, including $23.2 cardinal successful nett U.S. merchandise gross from IBTROZI, arsenic the institution said usage of the ROS1-targeted lung crab therapy continued to displacement toward first-line patients.

IBTROZI gross accrued 25% from the archetypal quarter, portion astir 160 patients began attraction during the period, Chief Executive Officer David Hung said. About 85% of those caller starts were successful the first-line setting, compared with astir 30% astatine motorboat little than a twelvemonth earlier. The institution said first-line starts roseate astir 30% sequentially.

IBTROZI adoption shifts toward first-line usage

→ Sandisk Just Delivered a Blowout Quarter—Here's Why the Stock Is Falling

Hung said Nuvation views gross arsenic the main measurement of IBTROZI's commercialized performance, but provided patient-start figures to exemplify changing motorboat dynamics. The institution said it has treated galore of the disposable later-line, TKI-pretreated patients since the drug's approval, portion first-line patients are expected to stay connected therapy longer.

"We expected first-line patients to go the main operator of semipermanent maturation owed to the overmuch longer duration of attraction successful the first-line setting, and we spot this dynamic happening successful existent time," Hung said.

→ 4 Oil and Gas ETF Plays arsenic Prices Stay Sky-High

Chief Commercial Officer Colleen Sjogren said IQVIA claims information from January done May showed IBTROZI was the astir prescribed ROS1 tyrosine kinase inhibitor, oregon TKI, crossed each attraction lines successful 2026. She added that physicians chose IBTROZI for much than fractional of recently treated first-line patients during that period.

Read Entire Article